Free Newsletter
Specialty drugmakers lobbying together
Here's a quandary: You're a good-sized drugmaker, but not a behemoth able to throw your weight around the industry's big trade associations. So how do you get your voice heard in our nation's capital? Form your own association, of course. That's exactly what Celgene, Cephalon, Cubist, Endo, Millennium, Purdue and Sepracor are doing: Banding together under the name America's Specialty Medicines Companies, and hiring a D.C. law firm for help getting organized.
What might this assortment's key issues be? That's unclear as yet. But you can bet we'll hear more from them as time goes by.
- read the item at In Vivo
Related Articles:
Dems swayed by pharma lobbying push
PhRMA plows $22M into 2007 lobbying
Millennium spent $1.3M on lobbying
Pharma lobbies big-time in '07
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession






SHARE
WITH: